CA Stock MarketDetailed Quotes
NGEN NervGen Pharma Corp
- 2.400
- +0.040+1.69%
15min DelayTrading Oct 15 09:30 ET
168.43MMarket Cap-6315P/E (TTM)
2.400High2.390Low10.57KVolume2.390Open2.360Pre Close25.28KTurnover3.98052wk High0.02%Turnover Ratio70.18MShares1.58052wk Low-0.38EPS TTM132.77MFloat Cap3.980Historical HighLossP/E (Static)55.32MShs Float0.800Historical Low-0.38EPS LYR0.42%Amplitude--Dividend TTM13.48P/B1Lot Size--Div YieldTTM
About NervGen Pharma Corp Company
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Company Profile
SymbolNGEN
Company NameNervGen Pharma Corp
Founded2017
MarketTSX
Employees11
Fiscal Year Ends12-31
Address112-970 Burrard Street Unit 1290
CityVancouver
CountryCAN
Zip CodeV6Z 2R4
Phone+1 778 731-1711
Websitehttps://www.nervgen.com
Company Executives
- Name
- Position
- Salary
- Michael Kelly
- Director, President and Chief Executive Officer
- --
- William J. Adams
- Chief Financial Officer and Corporate Secretary
- --
- Dr. Daniel D. Mikol, M.D.
- Chief Medical Officer
- --
- Dr. Adam H. Rogers, M.D.
- Director
- --
- Krista L. McKerracher
- Independent Director
- --
- Brian Eric Bayley
- Independent Director
- --
- Dr. Randall E. Kaye,M.D.
- Independent Director
- --
- Dr. Harold M. Punnett
- Independent Director
- --
- John Craig Thompson
- Independent Director
- --
- Glenn A. Ives
- Independent Director
- --
- Gianni Ruffolo
- Independent Director
- --
Heat List
CA
Overall
Symbol
Latest Price
% Chg
No Data